PT2402005T - Formulações de libertação sustentada de nalbufina - Google Patents

Formulações de libertação sustentada de nalbufina

Info

Publication number
PT2402005T
PT2402005T PT111789129T PT11178912T PT2402005T PT 2402005 T PT2402005 T PT 2402005T PT 111789129 T PT111789129 T PT 111789129T PT 11178912 T PT11178912 T PT 11178912T PT 2402005 T PT2402005 T PT 2402005T
Authority
PT
Portugal
Prior art keywords
nalbuphine
sustained release
release formulations
formulations
sustained
Prior art date
Application number
PT111789129T
Other languages
English (en)
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Publication of PT2402005T publication Critical patent/PT2402005T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT111789129T 2005-08-24 2006-08-24 Formulações de libertação sustentada de nalbufina PT2402005T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71077205P 2005-08-24 2005-08-24
US77246606P 2006-02-10 2006-02-10

Publications (1)

Publication Number Publication Date
PT2402005T true PT2402005T (pt) 2021-04-14

Family

ID=37772363

Family Applications (2)

Application Number Title Priority Date Filing Date
PT111789129T PT2402005T (pt) 2005-08-24 2006-08-24 Formulações de libertação sustentada de nalbufina
PT67899641T PT1931315E (pt) 2005-08-24 2006-08-24 Formulações de libertação sustentada de nalbufina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT67899641T PT1931315E (pt) 2005-08-24 2006-08-24 Formulações de libertação sustentada de nalbufina

Country Status (10)

Country Link
US (2) US8771732B2 (pt)
EP (2) EP2402005B1 (pt)
JP (1) JP2009506059A (pt)
CA (2) CA2881739C (pt)
DK (2) DK2402005T3 (pt)
ES (2) ES2441766T3 (pt)
HU (1) HUE053838T2 (pt)
PL (2) PL1931315T3 (pt)
PT (2) PT2402005T (pt)
WO (1) WO2007025005A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452871C (en) 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP5269595B2 (ja) * 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
ES2541809T3 (es) * 2007-10-16 2015-07-24 Paladin Labs Inc. Composición bicapa para la liberación sostenida de acetaminofeno y tramadol
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES
JP2011530529A (ja) * 2008-08-07 2011-12-22 アバントール パフォーマンス マテリアルズ， インコーポレイテッド ゴムおよび糖アルコールを含む徐放性組成物
EP2367541B1 (en) * 2008-12-16 2014-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2963889B1 (fr) 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
CA2834735C (en) 2011-04-29 2021-06-01 University Of Medicine And Dentistry Of New Jersey Use of nalbuphine for treating dyskinesia
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
AU2013359017B2 (en) * 2012-12-14 2018-05-10 Trevi Therapeutics, Inc. Methods for treating pruritus
AU2015274327A1 (en) * 2014-06-13 2017-01-05 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2017100971A (ja) * 2015-11-30 2017-06-08 株式会社ファンケル 錠剤
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
EP3826635A4 (en) * 2018-07-23 2022-04-27 Trevi Therapeutics, Inc. TREATMENT OF CHRONIC COUGH, DIFFICULT BREATHING AND DYSPNEA
US20240131022A1 (en) * 2022-03-11 2024-04-25 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237140A (en) * 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4282215A (en) * 1980-06-17 1981-08-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
US4404209A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and sulindac
US4407805A (en) * 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and zomepirac
US4404210A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and ibuprofen
US4407804A (en) * 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and indomethacin
US4404208A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
US4404211A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and flurbiprofen
US4402962A (en) * 1982-06-30 1983-09-06 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) * 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
DE69427551T2 (de) 1993-03-15 2002-05-16 National Science Council, Taipeh/T'ai-Pei Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5750534A (en) * 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6806294B2 (en) * 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE279186T1 (de) * 1999-08-31 2004-10-15 Gruenenthal Gmbh Retardierte darreichungsform enthaltend tramadolsaccharinat
PT1207860E (pt) * 1999-09-02 2008-01-24 Nostrum Pharmaceuticals Inc Formulação de peletes de libertação controlada
BR0013719A (pt) * 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Dosagem oral de liberaçâo controlada, apropriada para administração oral
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
DE60001487T2 (de) 2000-04-27 2003-12-24 Oliver Yoa-Pu Hu Polynalbuphinderivat
EP1292307A2 (en) 2000-06-09 2003-03-19 The Regents of The University of California Method of treating pain using nalbuphine and opioid antagonists
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
CN100356907C (zh) * 2001-06-08 2007-12-26 恩德制药公司 利用丙烯酸酯聚合物的控释剂型和其制备方法
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
JP4865330B2 (ja) * 2002-12-13 2012-02-01 デュレクト コーポレーション 経口ドラッグデリバリーシステム
EP1572164A2 (en) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1603597B1 (en) * 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
WO2005034859A2 (en) * 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US20060111382A1 (en) * 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain

Also Published As

Publication number Publication date
EP1931315A2 (en) 2008-06-18
PL2402005T3 (pl) 2021-11-22
US20070048376A1 (en) 2007-03-01
DK1931315T3 (da) 2014-01-20
US9186330B2 (en) 2015-11-17
ES2441766T3 (es) 2014-02-06
HUE053838T2 (hu) 2021-07-28
EP2402005B1 (en) 2020-12-16
CA2620224A1 (en) 2007-03-01
EP1931315B1 (en) 2013-10-16
DK2402005T3 (da) 2021-03-15
JP2009506059A (ja) 2009-02-12
WO2007025005A3 (en) 2007-12-21
WO2007025005A2 (en) 2007-03-01
US8771732B2 (en) 2014-07-08
CA2620224C (en) 2015-11-24
EP2402005A1 (en) 2012-01-04
PL1931315T3 (pl) 2014-09-30
US20140315937A1 (en) 2014-10-23
ES2862573T3 (es) 2021-10-07
CA2881739A1 (en) 2007-03-01
PT1931315E (pt) 2014-01-03
CA2881739C (en) 2018-01-02

Similar Documents

Publication Publication Date Title
HUE053838T2 (hu) Nyújtott felszabadulású nabulfin-készítmények
IL246026A0 (en) Delayed release of anti-infectives
HK1200092A1 (en) Sustained release formulations
IL184460A0 (en) Sustained release pharmaeutical formulations
IL185800A0 (en) Controlled release formulations of octreotide
ZA200707250B (en) Extended release formulation of levetiracetam
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
GB0406819D0 (en) Controlled release compositions
IL188964A0 (en) Sustained drug release composition
EP1883406A4 (en) COMPOSITIONS AND METHOD FOR CONTINUOUS RELEASE OF BETA-ALLANINE
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
EP1714643A4 (en) PREPARATION WITH DELAYED RELEASE
SI1732548T2 (sl) Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
EP1951693A4 (en) SOLID FORMULATIONS
IL178383A0 (en) Delayed release formulations of 6-mercaptopurine
IL190865A0 (en) Formulations of quinolinones
ZA200705011B (en) Formulations of substituted benzoxazoles
IL177328A0 (en) Controlled release formulations
EP1871348A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
IL198169A0 (en) Robust sustained release formulations of oxymorphone
ZA200803213B (en) Formulations of quinolinones
AP2006003706A0 (en) Controlled release pharmaceutical compositions